Bioavailability of griseofulvin peg ultramicrosize (Gris-Peg (R) ) tablets in man under steady-state conditions


Barrett, W.E.; Hanigan, J.J.

Current Therapeutic Research 18(3): 491-500

1975


In a double-blind, steady state, cross over design, 17 male subjects received either griseofulvin in a PEG formation (250 mg b.i.d.) or 500 mg microsize griseofulvin for 13 consecutive days.